| 1 |
Heidler F, Baldt J, Frahm N, Langhorst SE, Mashhadiakbar P, Streckenbach B, Burian K, Zettl UK, Richter J. Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic. Sci Rep 2022;12:15147. [PMID: 36071083 DOI: 10.1038/s41598-022-18912-3] [Reference Citation Analysis]
|
| 2 |
Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 3 |
Streckenbach B, Baldt J, Heidler F, Frahm N, Langhorst SE, Mashhadiakbar P, Burian K, Zettl UK, Richter J. General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.04.012] [Reference Citation Analysis]
|
| 4 |
Ruck T, Bock S, Pfeuffer S, Schroeter CB, Cengiz D, Marciniak P, Lindner M, Herrmann A, Liebmann M, Kovac S, Gola L, Rolfes L, Pawlitzki M, Opel N, Hahn T, Dannlowski U, Pap T, Luessi F, Schreiber JA, Wünsch B, Kuhlmann T, Seebohm G, Tackenberg B, Seja P, Döring F, Wischmeyer E, Chasan AI, Roth J, Klotz L, Meyer Zu Hörste G, Wiendl H, Marschall T, Floess S, Huehn J, Budde T, Bopp T, Bittner S, Meuth SG. K(2P)18.1 translates T cell receptor signals into thymic regulatory T cell development. Cell Res 2022;32:72-88. [PMID: 34702947 DOI: 10.1038/s41422-021-00580-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 5 |
Monschein T, Hartung HP, Zrzavy T, Barnett M, Boxberger N, Berger T, Chataway J, Bar-Or A, Rommer PS, Zettl UK. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry 2021;92:1033-43. [PMID: 34353858 DOI: 10.1136/jnnp-2021-326839] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 6 |
Pawlitzki M, Meuth SG. Immunmodulatorische Therapien bei Multipler Sklerose in der Pandemie. InFo Neurologie 2021;23:38-47. [DOI: 10.1007/s15005-021-2009-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurol Neuroimmunol Neuroinflamm 2021;8:e1035. [PMID: 34261812 DOI: 10.1212/NXI.0000000000001035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 8 |
Monschein T, Zrzavy T, Löbermann M, Winkelmann A, Berger T, Rommer P, Hartung HP, Zettl UK. [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 1: recommendations]. Nervenarzt 2021. [PMID: 34232359 DOI: 10.1007/s00115-021-01155-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Ospelnikova TP, Shitova AD. Possible biomarkers of therapy effective. РНЖ 2021;26:4-14. [DOI: 10.30629/2658-7947-2021-26-1-4-14] [Reference Citation Analysis]
|
| 10 |
Memon AB, Stec N, Bulka H, Cerghet M. COVID-19 and Autoimmune Demyelinating Diseases. Neurological Care and the COVID-19 Pandemic 2021. [DOI: 10.1016/b978-0-323-82691-4.00010-8] [Reference Citation Analysis]
|
| 11 |
Berlit P, Bösel J, Gahn G, Isenmann S, Meuth SG, Nolte CH, Pawlitzki M, Rosenow F, Schoser B, Thomalla G, Hummel T. "Neurological manifestations of COVID-19" - guideline of the German society of neurology. Neurol Res Pract 2020;2:51. [PMID: 33283160 DOI: 10.1186/s42466-020-00097-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 12 |
Berlit P. S1-Leitlinie: Neurologische Manifestationen bei COVID-19. DGNeurologie 2020;3:495-519. [DOI: 10.1007/s42451-020-00254-x] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 13 |
Dubey AK, Singh A, Prakash S, Kumar M, Singh AK. Race to arsenal COVID-19 therapeutics: Current alarming status and future directions. Chem Biol Interact 2020;332:109298. [PMID: 33121920 DOI: 10.1016/j.cbi.2020.109298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
